No Data
No Data
No Data
No Data
No Data
Benchmark: Restated Unicycive Therapeutics (UNCY.US) rating and adjusted from Speculative Buy to Specified Buy, target price of $3.00.
Benchmark: Restated Unicycive Therapeutics (UNCY.US) rating and adjusted from Speculative Buy to Specified Buy, target price of $3.00.
Zhitong FinanceApr 15 23:00
Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics with a Speculative Buy and maintains $3 price target.
Analyst UpgradesApr 15 23:00
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
TipRanksApr 12 03:05
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or
GlobeNewswireApr 10 19:03
Unicycive Therapeutics Initiated at Overweight by Piper Sandler
Unicycive Therapeutics Initiated at Overweight by Piper Sandler
Dow JonesApr 4 19:13
Piper Sandler Initiates Coverage On Unicycive Therapeutics With Overweight Rating, Announces Price Target of $9
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Unicycive Therapeutics with a Overweight rating and announces Price Target of $9.
Analyst UpgradesApr 4 19:03
No Data
No Data